Every 10-Q that Enliven Therapeutics, Inc. (ELVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELVN filings page.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on small-molecule precision therapies. The company is prioritizing ELVN-001 from its BCR-ABL program and preparations for a planned pivotal trial, while exploring strategic alternatives for ELVN-002 and discontinuing its development.
As of June 30, 2026, Enliven held $895.2 million in cash, cash equivalents and marketable securities and reported total stockholders’ equity of $895.1 million, with 73,270,761 common shares outstanding as of July 28, 2026. Management states this liquidity is expected to fund operating expenses and capital needs for at least 12 months.
For the quarter ended June 30, 2026, research and development expense was $28.996 million and general and administrative expense was $8.213 million, leading to a net loss of $32.485 million (basic and diluted net loss per share $0.49). For the first half of 2026, net loss was $56.112 million, with $21.312 million of stock-based compensation. A June 2026 underwritten offering raised aggregate gross proceeds of $460.0 million via common stock and pre-funded warrants, significantly strengthening the balance sheet.
Enliven Therapeutics reported a net loss of $23.6M, or $0.38 per share, for the three months ended March 31, 2026, compared with a $28.5M loss a year earlier. Research and development spending declined to $20.7M, while general and administrative expenses were $7.1M. The company ended the quarter with $452.4M in cash, cash equivalents and marketable securities, which management believes will fund operations for at least 12 months. Enliven is prioritizing its BCR-ABL program, advancing ELVN-001 toward a pivotal trial, and is exploring strategic alternatives for ELVN-002 and has decided not to develop its HER2 program beyond 2025.
Enliven Therapeutics (ELVN) reported Q3 2025 results. Operating expenses were $25.1 million, driven by research and development of $18.2 million and general and administrative of $6.9 million. The company recorded a net loss of $20.1 million, or $0.32 per share, compared with a net loss of $23.2 million a year ago.
Cash, cash equivalents and marketable securities totaled $477.6 million as of September 30, 2025, supported by a June underwritten public offering of 9,920,987 shares and pre-funded warrants to purchase 1,780,263 shares, delivering $230.0 million gross proceeds. Net cash used in operating activities for the nine months was $54.5 million. Shares outstanding were 59,347,317 as of October 31, 2025.
The company filed an automatic shelf on August 13, 2025 and added an at-the-market program covering up to $200.0 million of common stock; no sales occurred under the program during the period. Management states existing liquidity will fund planned operating expenses and capital requirements for at least 12 months from issuance.